Enveric Biosciences (ENVB) Stock Price, News & Analysis

-0.06 (-6.67%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
210,204 shs
Average Volume
1.25 million shs
Market Capitalization
$6.51 million
P/E Ratio
Dividend Yield
Price Target

Enveric Biosciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
1,090.5% Upside
$10.00 Price Target
Short Interest
1.07% of Float Sold Short
Dividend Strength
News Sentiment
-0.17mentions of Enveric Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.98) to ($1.02) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.23 out of 5 stars

ENVB stock logo

About Enveric Biosciences Stock (NASDAQ:ENVB)

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

ENVB Stock Price History

ENVB Stock News Headlines

Enveric Biosciences Inc (ENVB)
Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?
See More Headlines
Receive ENVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.84 per share


Free Float
Market Cap
$6.51 million
Not Optionable
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Joseph Edward Tucker Ph.D. (Age 55)
    CEO & Director
    Comp: $450.79k
  • Mr. Kevin M. Coveney CPA (Age 60)
    Chief Financial Officer
    Comp: $385.62k
  • Dr. Peter J. Facchini Ph.D. (Age 60)
    Chief Innovation Officer
    Comp: $233.27k

ENVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Enveric Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENVB shares.
View ENVB analyst ratings
or view top-rated stocks.

What is Enveric Biosciences' stock price target for 2024?

1 analysts have issued 1 year target prices for Enveric Biosciences' stock. Their ENVB share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,090.5% from the stock's current price.
View analysts price targets for ENVB
or view top-rated stocks among Wall Street analysts.

How have ENVB shares performed in 2024?

Enveric Biosciences' stock was trading at $1.30 at the start of the year. Since then, ENVB shares have decreased by 35.4% and is now trading at $0.84.
View the best growth stocks for 2024 here

When is Enveric Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ENVB earnings forecast

How were Enveric Biosciences' earnings last quarter?

Enveric Biosciences, Inc. (NASDAQ:ENVB) issued its quarterly earnings results on Monday, March, 25th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.09.

What ETF holds Enveric Biosciences' stock?

AdvisorShares Psychedelics ETF holds 278,833 shares of ENVB stock, representing 3.47% of its portfolio.

When did Enveric Biosciences' stock split?

Shares of Enveric Biosciences reverse split on the morning of Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Enveric Biosciences?

Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENVB) was last updated on 5/19/2024 by Staff

From Our Partners